Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

R B Verheijen; E L Swart; J H Beijnen; J H M Schellens; A D R Huitema; N Steeghs

doi:10.1007/s00280-020-04090-4

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

R B Verheijen^*, E L Swart, J H Beijnen, J H M Schellens, A D R Huitema, N Steeghs

^*Corresponding author for this work

Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands. [email protected].
University Medical Center Utrecht
Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Correction to: Cancer Chemother Pharmacol (2017) 80:1171–1178 https://doi-org.proxy.library.uu.nl/10.1007/s00280-017-3463-x

Original language	English
Article number	163
Number of pages	1
Journal	Cancer Chemotherapy and Pharmacology
Volume	86
Issue number	1
DOIs	https://doi.org/10.1007/s00280-020-04090-4
Publication status	Published - Jul 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-020-04090-4

Verheijen2020_Article_CorrectionToExposure-survivalAFinal published version, 315 KBLicence: Taverne

Cite this

@article{6b96403eca294f9c909b0b25ca43939c,

title = "Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization",

abstract = "Correction to: Cancer Chemother Pharmacol (2017) 80:1171–1178 https://doi-org.proxy.library.uu.nl/10.1007/s00280-017-3463-x",

author = "Verheijen, {R B} and Swart, {E L} and Beijnen, {J H} and Schellens, {J H M} and Huitema, {A D R} and N Steeghs",

year = "2020",

month = jul,

doi = "10.1007/s00280-020-04090-4",

language = "English",

volume = "86",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

AU - Verheijen, R B

AU - Swart, E L

AU - Beijnen, J H

AU - Schellens, J H M

AU - Huitema, A D R

AU - Steeghs, N

PY - 2020/7

Y1 - 2020/7

N2 - Correction to: Cancer Chemother Pharmacol (2017) 80:1171–1178 https://doi-org.proxy.library.uu.nl/10.1007/s00280-017-3463-x

AB - Correction to: Cancer Chemother Pharmacol (2017) 80:1171–1178 https://doi-org.proxy.library.uu.nl/10.1007/s00280-017-3463-x

U2 - 10.1007/s00280-020-04090-4

DO - 10.1007/s00280-020-04090-4

M3 - Article

C2 - 32524189

SN - 0344-5704

VL - 86

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 1

M1 - 163

ER -

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this